
New technique could be used to choose best therapies for patients and measure their effectiveness
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient’s progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.
Scientists at The Neuro (Montreal Neurological Institute-Hospital) of McGill University and the Ludmer Centre for Neuroinformatics and Mental Health used an AI algorithm to analyze the blood and post-mortem brain samples of 1969 patients with Alzheimer’s and Huntington’s disease. Their goal was to find molecular patterns specific to these diseases.
The algorithm was able to detect how these patients’ genes expressed themselves in unique ways over decades. This offers the first long-term view of molecular changes underlying neurodegeneration, an important accomplishment because neurodegenerative diseases develop over years.
Previous studies of neurodegeneration often used static or “snapshot” data, and are therefore limited in how much they can reveal about the typically slow progression of disease. This study aimed to uncover the chronological information contained in large-scale data by covering decades of disease progression, revealing how changes in gene expression over that time are related to changes in the patient’s condition.
Furthermore, the blood test detected 85 to 90 per cent of the top predictive molecular pathways that the test of post-mortem brain data did, showing a striking similarity between molecular alterations in both the brain and peripheral body.
“This test could one day be used by doctors to evaluate patients and prescribe therapies tailored to their needs,” says Yasser Iturria-Medina, the study’s first author. “It could also be used in clinical trials to categorize patients and better determine how experimental drugs impact their predicted disease progression.”
Iturria-Medina says his next steps will be testing these models in other diseases such as Parkinson’s disease and amyotrophic lateral sclerosis.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
AI-analyzed blood test
- My Mom Says She Loves Me. AI Says She’s Lying.
The tool is called Coyote. Trained on a data set of transcripts in which people were established as having lied or told the truth, the machine-learning model then tells you whether a statement is ...
- Predicting Astronauts' Health in Space Through Blood Analysis
Blood sample analysis helps predict and manage physiological changes in astronauts, ensuring their health and well-being during space missions.
- This AI diagnoses various diseases using the temperature of your face
Variations in facial temperature could soon enable early detection of diseases thanks to artificial intelligence (AI ... The researchers also analyzed blood samples and discovered that increased ...
- AI Better at Predicting Progression to Alzheimer's Than Standard Care
An AI program can outperform doctors at predicting which early dementia patients will progress to Alzheimer’s disease AI was about three times more accurate at predicting the progression to ...
- Three AI Technologies Poised to Transform IBD Care
Experts are optimistic that image analysis, natural language processing, and generative AI will soon become foundational to the management of patients with IBD.
Go deeper with Google Headlines on:
AI-analyzed blood test
[google_news title=”” keyword=”AI-analyzed blood test” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Neurodegenerative disease
- Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brainThese tools have the potential to be used to stratify ...
- Neurodegenerative diseases therapeutics market to grow by $21.29b by 2028
It is driven by a strong drug development pipeline. The global market for neurodegenerative diseases therapeutics is projected to grow by $21.29b from 2024 to 2028, at a compound annual growth rate of ...
- Neurodegenerative Diseases Therapeutics Market Size Is Set To Grow By USD...
The global neurodegenerative diseases therapeutics market size is estimated to grow by USD 21.29 billion from 2024-20 ...
- Alpha Cognition’s ZUNVEYL Receives FDA Approval to Treat Alzheimer’s Disease
The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer's disease as it's only the second oral AD treatment to be approved in more than a decade," said CEO Michael McFadden of Alpha ...
- Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39%
Anavex Life Sciences Corp. (NASDAQ:AVXL) presented comprehensive results from the Phase 2b/3 study showing that blarcamesine (ANAVEX2-73), once daily orally, significantly slowed clinical decline in ...
Go deeper with Google Headlines on:
Neurodegenerative disease
[google_news title=”” keyword=”neurodegenerative disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]